Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced that its management team will participate in two upcoming investor conferences in May 2026. The first is the RBC Capital Markets Global Healthcare Conference on May 19 in New York, followed by A.G.P.’s Annual Virtual Healthcare Conference on May 20. These presentations provide an opportunity for the company to update the investment community on its progress and pipeline developments.
Tonix focuses on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), recently received approval and is the first new treatment for fibromyalgia in over 15 years. Tonix’s CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. The company is exploring TONMYA’s potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder.
In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. The company is also advancing immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. These product candidates are investigational and not yet approved.
For more details, the full press release is available at https://ibn.fm/ZZpG2 and the latest news on TNXP can be found at https://ibn.fm/TNXP.
